26 research outputs found
¿Por qué están aumentando las infecciones de transmisión sexual entre jóvenes y adolescentes?
Noticia publicada en The Conversation España, el 05/07/2023.Nos pueden sonar a enfermedades del pasado, pero la sífilis y la infección gonocócica (gonorrea) están muy de actualidad. Forman parte de las denominadas infecciones de transmisión sexual (ITS), y se han descrito más de veinte microorganismos, entre virus, bacterias y parásitos, que pueden producirlas. Las cifras son preocupantes. Según la Organización Mundial de la Salud, en 2020 se produjeron un total de 374 millones de nuevos casos de las llamadas ITS curables (sífilis, gonorrea, infección por Chlamydia trachomatis y tricomoniasis) entre la población mundial de 15 a 49 años.N
Estudio de efectividad vacunal frente al mpox (Monkeypox)
Se incluye PDF de la presentación y vídeo del seminario.El mpoxv (antes virus de monkeypox) es un orthopoxvirus que causa una infección similar a la viruela, aunque más leve Es una enfermedad zoonótica localizada en África central y Occidental que se transmite por contacto animales humanos y por contacto directo de persona a persona. Las complicaciones se producen en el 8,2% y se deben infección bacteriana secundaria, úlceras bucales, proctitis/ protocolitis e infección corneal. Se propone la vacunación por parte de las autoridades sanitarias a la población en riesgo.N
Vigilancia epidemiológica de la infección por el VIH: Situación en la Unión Europea y en España, 2018
[ES] A continuación se presentan los principales resultados de la vigilancia de la infección por el virus
de la inmunodeficiencia humana (VIH) en los países de la Unión Europa/Área Económica Europa (UE/
AEE) y España correspondientes al año 2018, así como las tendencias en España en el periodo 2009-
2018. La tasa de nuevos diagnósticos de VIH en España en 2018 fue superior a la media de la UE/
AEE (8,6/100.000 habitantes en España y 5,8 en la UE/AEE, corregidas por retraso en la notificación),
aunque es similar a la de otros países del entorno. La vía de transmisión más importante sigue siendo
la sexual, ocupando el primer lugar las relaciones sexuales no protegidas entre hombres. Los datos
muestran, tanto en España como en la UE/AEE, que casi la mitad de los nuevos diagnósticos en
2018 fueron tardíos y la tendencia se mantiene estable en los últimos años. El grupo de edad más
afectado son los adultos entre 25 y 39 años. La tendencia de las tasas entre 2009 y 2018 es ligeramente
descendente, variando según la categoría de transmisión. Entre personas que se inyectan drogas y los
casos heterosexuales es decreciente. Por grupos de edad, la tendencia es descendente en todos ellos,
excepto entre 25 y 29 años que se mantiene estable.[EN] This report shows the main results about HIV surveillance in European Union/European Economic
Area (EU/EEA) and Spain in 2018, and the trends in Spain in the period 2009-2018. The rate of new
HIV diagnoses in Spain was higher than the average in UE/EEA (8.6/100.000 population in Spain and
5.8 in EU/EEA, adjusting for report delay), although is similar to other neighbor countries. Sexual
transmission is still the most important route of transmission, and the unprotected sexual relationships
between men were the highest proportion of cases. In Spain, as well as EU/EEA countries, nearly
half of new HIV diagnosed in 2018 were late presenters and the trend remains stable. Adults aged
between 25 and 39 years were the largest age group. The rate trend is slightly decreased during the period 2009-2018, changing by category of transmission. Among persons who injecting drugs and
heterosexuals, the trend is descending. By age group, the trend is descending, except between 25 and
29 that remains stable.N
Impact of the COVID-19 pandemic on the epidemiological surveillance systems of HIV infection in Spain
[ES] Fundamentos: La pandemia de la COVID-19 afectó de forma indirecta a otras enfermedades transmisibles, como la infección por el virus de la inmunodeficiencia humana (VIH). El objetivo de este estudio fue evaluar el impacto de la pandemia de la COVID-19 en la vigilancia epidemiológica del VIH a través de indicadores epidemiológicos. Métodos: Se analizaron los datos recogidos en el Sistema de Información de Nuevos Diagnósticos de VIH (SINIVIH) en el periodo 2013-2021. Los indicadores epidemiológicos analizados fueron: 1) Retraso en la notificación de nuevos diagnósticos; 2) Infradiagnóstico de caso, calculado por mes y por cada año de diagnóstico; 3) Diagnóstico tardío, casos diagnosticados con menos de 350 células CD4/mm3. Resultados: Respecto al retraso en la notificación de nuevos diagnósticos, en 2022 se notificaron 2.770 casos diagnosticados en 2020, un 43,8% más respecto a los notificados en 2021 para ese año. Los casos diagnosticados por mes entre 2016 y 2019 seguían una tendencia constante. En 2020 se observó un descenso importante de diagnósticos entre marzo y mayo que no se recuperó al corregir por retraso en la notificación. Al comparar las tasas de casos diagnosticados en 2013 con los años sucesivos, se observó un descenso continuo que se interrumpía en el último año del periodo de estudio. El porcentaje de casos con diagnóstico tardío se mantuvo estable en el periodo de estudio (entre el 46% y el 50%), observándose un descenso al corregir por retraso en la notificación. Conclusiones: La vigilancia epidemiológica del VIH sufrió un importante retraso en la notificación. Se constata un descenso en los casos diagnosticados, en parte debido al confinamiento y la falta de acceso a pruebas diagnósticas. No se observan cambios en el diagnóstico tardío. [EN] Objective: The COVID-19 pandemic indirectly affected other communicable diseases, such as human immunodeficiency virus (HIV) infection. The aim of this paper was to evaluate the impact of the COVID-19 pandemic on the epidemiological surveillance of HIV through epidemiological indicators. Methods: Data collected in the New HIV Diagnosis Information System (SINIVIH, acronym in Spanish) in the period 2013-2021 was analyzed. The epidemiological indicators analyzed were: 1) Reporting delay of new diagnoses; 2) Under diagnosis of cases, calculated per month of diagnosis and for each year of diagnosis; 3) Late diagnosis, cases diagnosed with less than 350 CD4 cell/mm3. Results: Regarding the reporting delay of new diagnoses, in 2022 2,770 diagnoses were reported in 2020, 43.8% more than those reported in 2021 for that year. The cases diagnosed per month between 2016 and 2019 followed a constant trend. In 2020, a significant decrease in diagnoses was observed between March and May that was not recovered after correcting for reporting delay. When comparing the rates of cases diagnosed in 2013 with the successive years, a continuous decrease was interrupted in the last year of the study period. The percentage of cases with late diagnosis had remained stable in the study period (between 46% and 50%), and a decrease in this percentage was observed after correcting for reporting delay. Conclusions: The epidemiological surveillance of HIV suffered a significant reporting delay. A decrease in cases diagnosed is confirmed, partly due to lockdown and lack of access to the health system. Changes on late diagnosis is not observed.S
Estimates of mpox effective reproduction number in Spain, April-August 2022
We analysed the transmission of the human mpox virus in Spain by estimating the effective reproduction number of the disease from official surveillance data. Our computations show that this decreased steadily after an initial burst phase, dropping below 1 on July 12, and thus the outbreak was expected to reduce in the following weeks. Differences in trends were found across geographical regions of the country and across MSM and heterosexual populations.This research was partially supported by CIBER (Strategic Action for Monkeypox) – Consorcio Centro de Investigación Biomédica en Red – (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU.S
Vigilancia Epidemiológica del VIH/SIDA: situación en europa y en España, 2015
[ES] En este boletín se presentan los principales resultados de la vigilancia de la infección por VIH/sida
en los países de la Unión Europea/Área Económica Europea (UE/AEE) y España correspondientes al
año 2015. La tasa de nuevos diagnósticos de VIH en España fue superior a la media de la UE/AEE
(7,4/100.000 habitantes en España y 5,8 en la UE/AEE, sin corregir por retraso en la notificación),
aunque es similar a la de otros países del entorno. La vía de transmisión más importante sigue siendo
la sexual, ocupando el primer lugar las relaciones sexuales no protegidas entre hombres. Los datos
muestran, tanto en España como en la UE/AEE, que casi la mitad de los nuevos diagnósticos en 2015
fueron tardíos y la tendencia se mantiene estable en los últimos años. [EN] This report shows the main findings about HIV/AIDS surveillance in European Union/European Economic Area countries (EU/EEA) and Spain in 2015. The rate of new HIV diagnoses was 7.4 per 100,000 population in Spain and 5.8 in EU/EEA, without adjusting by reporting delay. Sexual transmission is the most important transmission route and the highest proportion of HIV diagnoses was reported in men who have sex with men. In Spain, as well as in EU/EEA countries, nearly half (47%) of new HIV diagnoses in 2015 were late presenters and the trend remains stable.N
Transmission Clusters, Predominantly Associated With Men Who Have Sex With Men, Play a Main Role in the Propagation of HIV-1 in Northern Spain (2013-2018)
Viruses of HIV-1-infected individuals whose transmission is related group phylogenetically in transmission clusters (TCs). The study of the phylogenetic relations of these viruses and the factors associated with these individuals is essential to analyze the HIV-1 epidemic. In this study, we examine the role of TCs in the epidemiology of HIV-1 infection in Galicia and the Basque County, two regions of northern Spain. A total of 1,158 HIV-1-infected patients from both regions with new diagnoses (NDs) in 2013-2018 were included in the study. Partial HIV-1 pol sequences were analyzed phylogenetically by approximately maximum-likelihood with FastTree 2. In this analysis, 10,687 additional sequences from samples from HIV-1-infected individuals collected in Spain in 1999-2019 were also included to assign TC membership and to determine TCs' sizes. TCs were defined as those which included viruses from ≥4 individuals, at least 50% of them Spaniards, and with ≥0.95 Shimodaira-Hasegawa-like node support in the phylogenetic tree. Factors associated to TCs were evaluated using odds ratios (OR) and their 95% CI. Fifty-one percent of NDs grouped in 162 TCs. Male patients (OR: 2.6; 95% CI: 1.5-4.7) and men having sex with men (MSM; OR: 2.1; 95% CI: 1.4-3.2) had higher odds of belonging to a TC compared to female and heterosexual patients, respectively. Individuals from Latin America (OR: 0.3; 95% CI: 0.2-0.4), North Africa (OR: 0.4; 95% CI: 0.2-1.0), and especially Sub-Saharan Africa (OR: 0.02; 95% CI: 0.003-0.2) were inversely associated to belonging to TCs compared to native Spaniards. Our results show that TCs are important components of the HIV-1 epidemics in the two Spanish regions studied, where transmission between MSM is predominant. The majority of migrants were infected with viruses not belonging to TCs that expand in Spain. Molecular epidemiology is essential to identify local peculiarities of HIV-1 propagation. The early detection of TCs and prevention of their expansion, implementing effective control measures, could reduce HIV-1 infections.This work was funded through Acción Estratégica en Salud Intramural (AESI), Instituto de Salud Carlos III, Project “Estudios sobre vigilancia epidemiológica molecular del VIH-1 en España,” PI16CIII/00033 and Project “Epidemiología molecular del VIH-1 en España y su utilidad para investigaciones biológicas y en vacunas“PI19CIII/0042; Red de Investigación en SIDA (RIS), Instituto de Salud Carlos III, Subdirección General de Evaluación y Fondo Europeo de Desarrollo Regional (FEDER), Plan Nacional ICDCI, project RD16ISCIII/0002/0004; and scientific agreements with Consellería de Sanidade, Government of Galicia (MVI 1004/16), and Osakidetza-Servicio Vasco de Salud, Government of Basque Country (MVI 1001/16).S
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
Objectives: To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018-2021. Methods: We used multivariable regression models to compare viral suppression (VS) [HIV RNA viral load (VL) <50 copies/mL] and the change in CD4 cell counts at 24 and 48 (±12) weeks after initiation with dolutegravir/lamivudine or other first-line ART regimens. Results: We included 2160 treatment-naive subjects, among whom 401 (18.6%) started with dolutegravir/lamivudine. The remaining subjects started bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) (n = 949, 43.9%), DTG + FTC/tenofovir disoproxil fumarate (TDF) (n = 282, 13.1%), DTG/3TC/abacavir (ABC) (n = 255, 11.8%), darunavir (DRV)/cobicistat(COBI)/FTC/TAF (n = 147, 6.8%) and elvitegravir (EVG)/COBI/FTC/TAF (n = 126, 5.8%). At 24 and 48 weeks after starting dolutegravir/lamivudine, 91.4% and 93.8% of the subjects, respectively, achieved VS. The probability of achieving VS with dolutegravir/lamivudine was not significantly different compared with any other regimen at 24 or 48 weeks, with the exception of a lower chance of achieving VS at 24 weeks for DRV/COBI/FTC/TAF (adjusted OR: 0.47; 95% CI: 0.30-0.74) compared with dolutegravir/lamivudine.For the analysis of treatment-experienced virally suppressed subjects we included 1456 individuals who switched to dolutegravir/lamivudine, among whom 97.4% and 95.5% maintained VS at 24 and 48 weeks, respectively. During the first 48 weeks after dolutegravir/lamivudine initiation, 1.0% of treatment-naive and 1.5% of treatment-experienced subjects discontinued dolutegravir/lamivudine due to an adverse event. Conclusions: In this large multicentre cohort, effectiveness and tolerability of dolutegravir/lamivudine were high among treatment-naive and treatment-experienced subjects.This work was supported by (i) the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional I + D + i and co-financed by Instituto de Salud Carlos III-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER), and (ii) ViiV Healthcare. The funders did not play any decision making role in the design, execution, analysis or reporting of the research.S
Significant increase in azithromycin "resistance" and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019
Background: The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) performs annual sentinel surveillance of Neisseria gonorrhoeae susceptibility to therapeutically relevant antimicrobials across the European Union/European Economic Area (EU/EEA). We present the Euro-GASP results from 2019 (26 countries), linked to patient epidemiological data, and compared with data from previous years. Methods: Agar dilution and minimum inhibitory concentration (MIC) gradient strip methodologies were used to determine the antimicrobial susceptibility (using EUCAST clinical breakpoints, where available) of 3239 N. gonorrhoeae isolates from 26 countries across the EU/EEA. Significance of differences compared with Euro-GASP results in previous years was analysed using Z-test and the Pearson's χ2 test was used to assess significance of odds ratios for associations between patient epidemiological data and antimicrobial resistance. Results: European N. gonorrhoeae isolates collected between 2016 and 2019 displayed shifting MIC distributions for; ceftriaxone, with highly susceptible isolates increasing over time and occasional resistant isolates each year; cefixime, with highly-susceptible isolates becoming increasingly common; azithromycin, with a shift away from lower MICs towards higher MICs above the EUCAST epidemiological cut-off (ECOFF); and ciprofloxacin which is displaying a similar shift in MICs as observed for azithromycin. In 2019, two isolates displayed ceftriaxone resistance, but both isolates had MICs below the azithromycin ECOFF. Cefixime resistance (0.8%) was associated with patient sex, with resistance higher in females compared with male heterosexuals and men-who-have-sex-with-men (MSM). The number of countries reporting isolates with azithromycin MICs above the ECOFF increased from 76.9% (20/26) in 2016 to 92.3% (24/26) in 2019. Isolates with azithromycin MICs above the ECOFF (9.0%) were associated with pharyngeal infection sites. Following multivariable analysis, ciprofloxacin resistance remained associated with isolates from MSM and heterosexual males compared with females, the absence of a concurrent chlamydial infection, pharyngeal infection sites and patients ≥ 25 years of age. Conclusions: Resistance to ceftriaxone and cefixime remained uncommon in EU/EEA countries in 2019 with a significant decrease in cefixime resistance observed between 2016 and 2019. The significant increase in azithromycin "resistance" (azithromycin MICs above the ECOFF) threatens the effectiveness of the dual therapy (ceftriaxone + azithromycin), i.e., for ceftriaxone-resistant cases, currently recommended in many countries internationally and requires close monitoring.The study was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2017/004). The funding body designed, initiated and coordinated the study as well as assisted in the interpretation of the data, development and final approval of the manuscriptS